Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Eplontersen · Wainua

Oligonucleotide (Antisense oligonucleotide) · Gene silencing: transthyretin (TTR) · developed by Astrazeneca

Approved FDA, Dec 2023
AZN Developer

What is Eplontersen?

Eplontersen is an antisense oligonucleotide-GalNAc conjugate that binds TTR mRNA and causes its degradation, lowering serum transthyretin protein and TTR deposits in tissues. It is being studied in transthyretin amyloid cardiomyopathy and is used for the polyneuropathy of hereditary transthyretin-mediated amyloidosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Wainua
Drug type
Oligonucleotide (Antisense oligonucleotide)
Targets
transthyretin (TTR)
Mechanism
Gene silencing: transthyretin (TTR)
Pathways
TTR mRNA degradation, reduction of serum TTR protein and tissue TTR deposits
Therapy area
Cardiovascular, Neurology
Developer
Astrazeneca Ab (AZN)
FDA status
Approved as Wainua (December 21, 2023), NDA217388 · FDA label
UNII
0GRZ0F5XJ6

✅ FDA-approved uses

From the indications section of the FDA label (version of Apr 15, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Transthyretin Amyloid Cardiomyopathy

Other drugs acting on TTR

More from Astrazeneca

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Eplontersen

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.